HONG KONG (Reuters) - Beijing has given the go-ahead to a Chinese drugmaker to begin large-scale production of a human bird flu vaccine, after a second clinical trial showed the vaccine was safe and effective, the company said on Thursday.
The vaccine uses an inactivated whole H5N1 virus from Vietnam, said an official for Sinovac Biotech, which jointly developed the vaccine with China's Centres for Disease Control.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
